Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint
Globe Newswire•30/10/2026•07:00 ET
0
Key Highlights
- ➤ALTITUDE-AD missed its primary iADRS endpoint at 18 months for both doses
- ➤Key secondary endpoints, including CDR-SB, lacked statistical significance versus placebo
- ➤Acumen (ABOS) plans to cease sabirnetug development and close the open-label extension
- ➤Acumen will conserve cash and explore strategic options, including its EBD program
- ➤Sabirnetug reduced amyloid plaque load significantly at weeks 36 and 76
Expert Statements
Daniel O’Connell, Chief Executive Officer of Acumen Pharmaceuticals
“While we are disappointed the trial did not meet its primary endpoint, we express our compassion and hope for future therapeutic options for patients with Alzheimer’s disease and their families.”
Daniel O’Connell, Chief Executive Officer of Acumen Pharmaceuticals
“We have tremendous gratitude toward the patients, caregivers, investigators and clinical trial sites, as well as all Acumen employees, who worked so diligently over many years on this program.”
-- Topline data show that ALTITUDE-AD did not meet the primary endpoint of change from baseline in cognitive and functional decline as measured by the Integrated Alzheimer’s Disease Rating Scale (iADRS) at 18 months compared to placebo at either dose; key secondary endpoints, including CDR-SB, also did not achieve statistical significance --
-- Acumen to cease clinical development of sabirnetug, preserve cash and explore strategic options --
Get started
Create a free account to read the full story.